The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
04-Oct-16
$223 million
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
Target:
US rights to Toprol-XL (AstraZeneca)
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
08-Aug-11
$11.0 billion
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Target:
Coal and Allied Industries Limited
![Australia, Japan flags](https://www.greenhill.com/sites/default/files/aus-japan_45376.gif)
Acquiror:
Rio Tinto Limited / Mitsubishi Corporation
Advised Coal and Allied Industries Limited, an Australian based coal mining company, in relation to an acquisition proposal from Rio Tinto Limited and Mitsubishi Corporation to acquire all the outstanding shares in the company not already held by Rio Tinto and Mitsubishi
31-Jul-08
$10.3 billion
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Target:
TransAlta Corporation
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Acquiror:
LS Power Equity Partners / Global Infrastructure Partners
Advised TransAlta Corporation, a power generation and wholesale marketing company, on an unsolicited offer from LS Power Equity Partners / Global Infrastructure Partners